key: cord-0780846-zn6w1val
authors: Shah, Mansi R.; Gabel, Alissa; Beers, Stephanie; Salaru, Gratian; Lin, Yong; Cooper, Dennis L.
title: COVID-19 vaccine responses in patients with plasma cell dyscrasias after complete vaccination
date: 2021-11-11
journal: Clin Lymphoma Myeloma Leuk
DOI: 10.1016/j.clml.2021.11.001
sha: 5808d03fbd538f9cdba1e13eb239a5bcce9a8d98
doc_id: 780846
cord_uid: zn6w1val

Introduction: Due to functional hypogammaglobulinemia, multiple myeloma patients are at increased risk for infection and generally have poorer responses to vaccines. In this study, we examined antibody responses after complete COVID-19 vaccination in patients with plasma cell dyscrasias, most of whom were receiving treatment. Patients and Methods: Real world study of consecutive patients with multiple myeloma and other plasma cell dyscrasias (PCD) were evaluated after complete vaccination with either the 2-shot mRNA vaccines from BioNTech and Moderna or the 1-shot adenoviral vector vaccine from Johnson & Johnson (J&J). Patients received vaccines 1-4 months before antibody testing without controlling for the type of vaccine or the timing of drug therapy. Patients with a clinical history or antibody evidence of prior infection were excluded. Anti-nucleocapsid and quantitative anti-spike antibody levels were measured with the Roche Elecys assay. Results: 95% of patients had detectable antibody responses. Multivariate analysis showed that higher age, ongoing anti-CD38 monoclonal antibody therapy and the J&J vaccine negatively affected quantitative response. A small number of ineffectively vaccinated patients receiving IVIG subsequently had detectable nucleocapsid and spike antibodies confirming the presence of the latter in currently administered IVIG. Conclusions: Nearly all PCD had detectable anti-spike antibodies after vaccination but age, anti-CD38 monoclonal antibody therapy, and the single-shot J&J vaccine negatively affected responses. In patients who received the J&J vaccine, second doses or heterologous mRNA vaccines should be tested. Quantitative antibody testing might make future management more rational, particularly in patients with poor responses.

Conflict-of-interest disclosure: MRS, AG, SB, GS, YL and DLC have no conflicts of interest to declare.

Patients with multiple myeloma are at increased risk for infection due to functional hypogammaglobulinemia and therapy related immunosuppression and are vulnerable to severe infections from COVID-19. We evaluated antibody response to currently available vaccines against SARS-CoV-2 in patients with plasma cell dyscrasias, most of whom had multiple myeloma. 95% of patients responded with detectable anti-spike antibody levels. Older age, ongoing treatment with anti-CD38 mAb and the J&J adenoviral vector vaccine were negatively associated with antibody response.

Introduction: Due to functional hypogammaglobulinemia, multiple myeloma patients are at increased risk for infection and generally have poorer responses to vaccines. In this study, we examined antibody responses after complete COVID-19 vaccination in patients with plasma cell dyscrasias, most of whom were receiving treatment.

Patients and Methods: Real world study of consecutive patients with multiple myeloma and other plasma cell dyscrasias (PCD) were evaluated after complete vaccination with either the 2-shot mRNA vaccines from BioNTech and Moderna or the 1-shot adenoviral vector vaccine from Johnson & Johnson (J&J). Patients received vaccines 1-4 months before antibody testing without controlling for the type of vaccine or the timing of drug therapy. Patients with a clinical history or antibody evidence of prior infection were excluded. Anti-nucleocapsid and quantitative anti-spike antibody levels were measured with the Roche Elecys assay.

Results: 95% of patients had detectable antibody responses. Multivariate analysis showed that higher age, ongoing anti-CD38 monoclonal antibody therapy and the J&J vaccine negatively affected quantitative response. A small number of ineffectively vaccinated patients receiving IVIG subsequently had detectable nucleocapsid and spike antibodies confirming the presence of the latter in currently administered IVIG.

Conclusions: Nearly all PCD had detectable anti-spike antibodies after vaccination but age, anti-CD38 monoclonal antibody therapy, and the single-shot J&J vaccine negatively affected responses. In patients who received the J&J vaccine, second doses or heterologous mRNA vaccines should be tested. Quantitative antibody testing might make future management more rational, particularly in patients with poor responses.

Keywords: COVID-19, multiple myeloma, serologic response, vaccine boosters, immunocompromised Introduction:

Multiple myeloma (MM) is associated with abnormalities in innate and adaptive immunity 1 leading to an increased risk of mortality due to infection. Humoral immunity is compromised secondary to ineffective monoclonal gammopathy compounded by depression of uninvolved immunoglobulins and worsened by therapy-related immunosuppression. 2 Diminished T-cell responses, impaired renal function, and disease status are additional factors that may contribute to higher susceptibility to infections in patients with MM. 3, 4 The importance of the antibody response to SARS-CoV-2 infection recovery and vaccination has been recently demonstrated. A study of monoclonal antibody (mAb) therapy after SARS-CoV-2 infection showed benefit that was mainly limited to patients without detectable antibody at the time of administration whereas those with measurable antibody had few subsequent medical-attending events. 5 Similarly, after SARS-CoV-2 vaccination, normal volunteers were highly resistant to infection. 6, 7 However, the efficacy of first dose vaccines is lower in immunocompromised patients including patients with MM. 8, 9 Thus, there is considerable interest in assessing the antibody response after complete vaccination in MM patients. In this study, we examined antibody responses in previously uninfected patients with plasma cell dyscrasias (PCD), most of whom were receiving treatment. We were particularly interested in patients receiving anti-CD38 mAbs because of their increasing importance in front-line therapy [10] [11] [12] [13] and highly specific anti-plasma cell activity.

The Institutional Review Board (IRB) approved this retrospective analysis. The antibodies against SARS-CoV-2 nucleocapsid and spike protein were evaluated in patients with PCDs who received two doses of the mRNA vaccines BTN162b2 6 or mRNA-1273 7 , or one dose of the Ad26.COV.S 14 vaccines. We included patients with MM, smoldering multiple myeloma (SMM), solitary plasmacytoma, and AL amyloidosis with most patients on therapy. As this was a retrospective study, there was no attempt to control the type of vaccine that patients received nor was there a strategy of spacing treatment and vaccination.

After at least 14 days from the completion of vaccination, serum samples for nucleocapsid (indicating infection) and anti-spike SARS-CoV-2 antibodies were analyzed by using Elecsys Anti-SARS-CoV-2S assay on the Cobas e 601 with a positive detection threshold for the receptor-binding domain of S of at least 0.4U/mL, which correlates with neutralizing immunity mediated by vaccination. 15 The sensitivity and specificity of the immunoassay for the detection of spike antibodies in response to COVID-19 infections are 98.8% and 100%, respectively. 16 Because previous SARS-CoV-2 infection is known to strengthen the vaccine response 17, 18 we excluded patients with a history of prior infection or a positive nucleocapsid antibody. Antibody measurement was performed between the dates of 4.15.21 and 7.1.21 with nearly all patients vaccinated 1-4 months before testing.

As the mRNA vaccines were given emergency authorization and available first, most patients received the two-dose BTN162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines 21 and 28 days apart, respectively. 6, 7 Only 11 patients received the one-dose Ad26.COV2.S (Johnson &Johnson; J&J) vaccine. 14 122 patients were tested.

Thirty-three patients were excluded including 19 who had a prior history of COVID-19 infection and an additional 12 based on a positive nucleocapsid antibody detection. The demographics and responses of the study patients are shown in Table 1 . Figure 1 demonstrates a comparison of the responses in patients with severe immunoparesis and according to therapy type. Nearly all patients responded to the currently used SARS-CoV-2 vaccines but patients receiving anti-CD38 mAb had significantly lower titers. There was a higher response after the mRNA vaccines compared to the J&J vaccine, but the difference was not statistically significant in patients receiving anti-CD38 mAb therapy, possibly because of low patient numbers in the J&J group. After the J&J vaccine, 3 of 11 patients had anti-spike antibodies greater than 100 U/ml compared to 25 of 41 Pfizer-BioNTech and 28 of 37 Moderna patients. The 100 IU/ml target threshold is based on a preclinical study in baboons 19 and supported by a large clinical study. 20 Multivariate analysis in Table 2 showed that age, anti-CD38 antibody therapy and J&J vaccine negatively affected antibody response.

Two non-responding patients had HIV associated with low T cell counts, and there were 2 other non-responders. Interestingly, one of the latter patients subsequently received intravenous immunoglobulin (IVIG) and a second test was positive for both anti-nucleocapsid and anti-spike antibodies, suggesting possible transfer from the IVIG.

Accordingly, we tested three other patients with myeloma and 2 patients with lymphoma who had not been effectively vaccinated and all became positive for antibodies against the nucleocapsid and anti-spike proteins after IVIG administration. One patient in this study had COVID-19 infection after complete vaccination. Because the antibody titer was low at 15 U/ml, the patient was referred for monoclonal antibody therapy and recovered uneventfully. 20.8% received Nab levels felt to be clinically protective. 9 In a similar study from the UK (with vaccines given 12 weeks apart), only 54-58% of myeloma patients had a positive antibody response at a median of 33 days after the first vaccine with no difference between the Pfizer and ChAd0x1 (Astra-Zeneca) products. 8 Our results in patients who predominantly received 2-shot vaccines showed that that nearly all achieved a measurable antibody response, thereby implying the importance of the second vaccine in myeloma patients and suggesting that a 2-shot strategy should be considered for other pathogens in immunocompromised patients. In a recent study of myeloma patients, Branagan et al. found that tandem doses of high dose influenza vaccines resulted in higher and more durable serologic responses compared to the standard-ofcare single dose vaccine and this strategy will likely be incorporated in the International

Myeloma Network guidelines. 25 In patients who have received the J&J vaccine, it remains unclear whether they should be given a second shot with the same vaccine or an mRNA vaccine. Heterologous boosts are being tested and emerging results showed higher responses after the Pfizer mRNA vaccine than a second dose of the Astra-Zeneca ChAd0x1. 26 Interestingly, we found that in 4 MM patients and two lymphoma patients receiving IVIG, there was evidence of nucleocapsid and low-level anti-spike antibodies, most likely a consequence of transfer from the IVIG preparation. Romero et al. found that IVIG preparations began to routinely show anti-SARS-CoV-2 antibodies in the fall of 2020. 27 This would suggest that as a higher percentage of the population is vaccinated and/or infected, monthly IVIG might offer protection to immunocompromised patients. One small study of IVIG has shown a decrease in mortality with severe COVID-19 infection. 28 Though not currently recommended outside of clinical trials, during the course of the study it became apparent that quantitative measurement of antibody responses were informative and potentially important for rational future management. As an example, there was a significant number of patients with evidence of asymptomatic infection based on a positive anti-nucleocapsid result. The incidence of asymptomatic infection in MM or other immunocompromised populations is not well established, which suggests that estimates of mortality after SARS-CoV-2 infection are likely overestimated. 29, 30 In addition, while previously infected and vaccinated (I & V) patients cannot be considered completely protected against future disease, it is questionable whether these patients need a booster. We did not include previously infected patients in this study but the median antibody titer in the I & V population after vaccination was higher than the limit of the assay (> 2499 U/ml) (data not shown).

At the other end of the spectrum, patients with a zero or low antibody response to the vaccine need counseling regarding their continued vulnerability to infection including the  In this real-world study of consecutive patients with PCD, we examined antibody responses after the three available vaccines in the United States. We were particularly interested in the impact of different types of therapy, especially anti-CD38 mAb. We excluded patients with a clinical history or laboratory detection of prior infection.

 We found that nearly all patients (95%) had a detectable response but that lower responses were associated with older age, ongoing anti-CD38 mAb therapy and the J&J vaccine.

 Quantitative antibody measurement has the potential to make management of COVID-19 protection more rational. Clinical trials evaluating prophylactic monoclonal antibodies and other strategies for ineffectively vaccinated patients require further investigation. Some degree of passive immunity may also be possible after IVIG, which contains anti-spike antibodies reflecting the high prevalence of COVID-19 antibodies in the population secondary to infection and vaccination.

 In patients with prior J&J vaccine, second shots versus heterologous mRNA vaccine needs further exploration.

Tables: Figures: Figure 1 : A comparison of the responses in PCD patients according to type of vaccine, therapy, severe immunoparesis, and exposure to anti-CD38 mAb

The mRNA vaccines resulted in statistically higher responses compared to the J&J vaccine. However, the differences between the two mRNA vaccines were not statistically different from each other. There was a significantly lower response in MM patients treated with anti-CD38 mAb regardless of vaccine type.

Abbreviations: JJ, Johnson & Johnson; mAb, monoclonal antibody; MM, multiple myeloma

MGUS to myeloma: a mysterious gammopathy of underexplored significance

Immunosuppression and infection in multiple myeloma

Immunological factors and risk of infection in plateau phase myeloma

Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

Efficacy and Safety of the mRNA-1273 SARS-CoV-2

Safety and Efficacy of the BNT162b2 mRNA Covid-19

Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma

Low Neutralizing Antibody Responses Against SARS-CoV-2 in Elderly Myeloma Patients After the First BNT162b2 Vaccine Dose

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Development and validation of the Elecsys Anti-SARS-CoV-2 immunoassay as a highly specific tool for determining past exposure to SARS-CoV-2

SARS-CoV-2 detection, viral load and infectivity over the course of an infection

Prior COVID-19 Infection and Antibody Response to Single Versus Double Dose mRNA SARS-CoV-2 Vaccination. medRxiv

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

Responses to acute infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons and marmosets

Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients

Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma

Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia

Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. Leukemia

Safety and Immunogenicity Report from the Com-COV Study -a Single-Blind Randomised Non-Inferiority Trial Comparing Heterologous And Homologous Prime-Boost Schedules with An Adenoviral Vectored and mRNA COVID-19 Vaccine

Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products

The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial

A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward

COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers. medRxiv

SARS -CoV-2 T-cell immunity to variants of concern following vaccination. bioRxiv

Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion, France. Emerg Infect Dis

We thank the team at the Division of Blood Disorders for their support.

Contribution: M.R.S. designed the research, performed research, analyzed the data, and wrote the paper; A.G. and S.B. performed research and reviewed the paper; G.S.analyzed the data and reviewed the paper; Y.L. analyzed the data and reviewed the paper; and D.L.C designed the research, performed research, analyzed the data, and wrote the paper.